Medical Condition News

RSS

Some heart care costs stay outside insurance coverage, Lowe's does national comparison shopping for employees' heart surgery

MarketWatch reports that though many tout prevention in relation to heart disease, "chances are your insurance won't cover a trip to a dietician, a gym membership or other services that could help you reduce your risk factors."

18 Feb 2010

Researchers develop guidelines for assessment, treatment and management of lymphedema

Lymphedema, a chronic swelling condition that can appear after breast cancer surgery, is a risk for 1.3 million breast cancer survivors. Although lymphedema can cause lifelong swelling in the arms, back, neck and chest, there is no national standard of diagnosis or care.

18 Feb 2010

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Duke University Medical Center scientists crowded around a laser-powered microscope in a darkened room to peer into the brain of an anesthetized juvenile songbird right after he heard an adult tutors' song for the first time.

18 Feb 2010

EGS announces performance of 3,500th NOS procedure

EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today reported that the 3,500th Natural Orifice Surgery (NOS) procedure was performed in front of the over 110 surgeons from seven countries attending the first Advanced Techniques in Transoral Fundoplication CME course, held January 28-29 in Denver, CO.

18 Feb 2010

BG Medicine, Merck collaborate in development of novel biomarker for lipid disorder management

BG Medicine, Inc. today announced that it has entered into a research collaboration with Merck, through a subsidiary, for the development and validation of a novel biomarker with potential application in the management of lipid disorders. BG Medicine will pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.

18 Feb 2010

Obesity doubles the risk of developing kidney stones: Study

Obesity in general nearly doubles the risk of developing kidney stones, but the degree of obesity doesn't appear to increase or decrease the risk one way or the other, a new study from Johns Hopkins shows.

18 Feb 2010

People who are happy and content are less likely to develop heart disease

People who are usually happy, enthusiastic and content are less likely to develop heart disease than those who tend not to be happy, according to a major new study published today (Thursday 18 February).

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

It looks more like an iPod than a medical tool. But the latest miniature ultrasound device created by Cornell biomedical engineering graduate student George K. Lewis could one day introduce a whole new level of home therapy for arthritis, injury and other painful ailments.

18 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.

17 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Eat fruits and vegetables to prevent heart disease

As heart disease continues to be the leading cause of death in the United States for all adults, a new report released by the Nutrilite Health Institute, America's Phytonutrient Report: Heart Health by Color*, shows that Americans are falling short on heart-healthy phytonutrients.

17 Feb 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Otonomy, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere's disease, a debilitating disorder of the inner ear affecting balance and hearing.

17 Feb 2010

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

17 Feb 2010

Fourth-quarter and full-year 2009 results announced by Celsion

Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.

17 Feb 2010

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Cannabis Science Inc., an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

17 Feb 2010

Medical Condition News

Some heart care costs stay outside insurance coverage, Lowe's does national comparison shopping for employees' heart surgery

Researchers develop guidelines for assessment, treatment and management of lymphedema

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

EGS announces performance of 3,500th NOS procedure

BG Medicine, Merck collaborate in development of novel biomarker for lipid disorder management

Obesity doubles the risk of developing kidney stones: Study

People who are happy and content are less likely to develop heart disease

Ibuprofen may reduce risk of Parkinson's disease, says study

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Eat fruits and vegetables to prevent heart disease

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Fourth-quarter and full-year 2009 results announced by Celsion

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News